6Barbato E , Wijins W , De Bruyne B, et al. Current concepts and clinical applications of coronary beta adrenergic receptors, and their clinical applicatlions [ J ]. Recenti Prog Med, 2005 , 96 ( 9 ) : 411 - 415.
7Terashima M , Akita H , Kanazawa K ,et al. Circulating T-lymphocyte activation in patients with variant angina[ J ]. Coron Artery Dis, 2002 ,13(3) :161 - 168.
8Dishy V , Landau R , Sofowora GG , et al. Beta2-adrenoceptor Thr164lle polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo[ J ]. Pharmacogenetics, 2004 , 14 ( 8 ) :517 - 522.
二级参考文献26
1[2]Devereux RB,Alonso DR,Lelas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy finding.Am J Cardiol,1986,57:450-457.
2[5]Peng Y,Ma S,Zhang S,et al.Clinical significance of changes in beta-adrenoreceptors in peripheral lymphocytes in patients with essential hypertension.Chin Med J (Engl),2000,113(12):1064-1067.
3Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coil Cardiol, 1993,22:61A - 71A.
4Bredde OE, Kxetsch R, Ikezono K, et al. Human β-adrenoceptors:relation of myocardiac and lymphocyte β-adrenoceptors desity.Science,1986,231:1584-1585.
5Motulsky HJ, Cunningham EMS, Deblasi A, et al. Desensitation and redistribution of β-adrenergic receptors on human mononuclear leukocytes. Am J Physiol, 1986, 250:E583 -59O.
6Bristow MR, Minobe W, Rasmussen R, et al. Betaadrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest, 1992,89:803 - 815.
7Bristow MR, Hershberg RE, Port JD and Rasmussen R. Beta1-and beta2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol, 1989,35:295 - 303.
8Packer M. β-Blockade in heart failure-basic concepts and clinical results. Am J Hypertens, 1998,11:23 - 37.
9Heilbrunn SM, Shah P, Bristow MR, et al. Increased betareceptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation,1989,79 : 483 - 490.
10Edward M Gibert, et al. Comparative hemodymanic, left ventricular functional and antiadrenergic of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation, 1994,11:2817 - 2825.
4Xiao RP, Zhu WZ, Zheng M, et al. Subtype-specific α1-and β-adrenoceptor signaling in the heart[ J]. Trends Pharmacol Sci, 2006, 27(6) :330 -337.
5Xiao RP, Zhu WZ, Zheng M, et al. Subtype-specific β-adrenoceptot signaling pathways in the heart and their potential clinical implications[J]. Trends Pharmacol Sci, 2004, 25(7) :358 -365.
6POREBA R,DERKACZ A,SILBER M,et al.Assessment of cardiac arrhythmias in patients suffering from essential hypertension[J].Pol Arch Med Wewn,2004,111:183-189.
7GANAU A,DEVEREUX R B,ROMAN M J,et al.Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension[J].JAmCollCardiol,1992,19:1550-1558.
8MIRCOLI L,FEDELE L,BENETTI M,et al.Preservation of the baroreceptor heart rate reflex by chemical sympathectomy in experimental heart failure[J].Circulation,2002,106:866-867.
9LEVY D,GARRISON R,SAVAGE D,et al.Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study[J].N Engl J Med,1990,322:1561-1566.
10VAKILI B A,OKIN P M,DEVEREUX R B.Prognostic implications of left ventricular hypertrophy[J].Am Heart J,2001,141:334-341.
